JP2020528922A5 - - Google Patents

Info

Publication number
JP2020528922A5
JP2020528922A5 JP2020505412A JP2020505412A JP2020528922A5 JP 2020528922 A5 JP2020528922 A5 JP 2020528922A5 JP 2020505412 A JP2020505412 A JP 2020505412A JP 2020505412 A JP2020505412 A JP 2020505412A JP 2020528922 A5 JP2020528922 A5 JP 2020528922A5
Authority
JP
Japan
Prior art keywords
carbon atoms
groups
trisubstituted
disubstituted
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020505412A
Other languages
English (en)
Japanese (ja)
Other versions
JP7336434B2 (ja
JP2020528922A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/067797 external-priority patent/WO2019025099A1/en
Publication of JP2020528922A publication Critical patent/JP2020528922A/ja
Publication of JP2020528922A5 publication Critical patent/JP2020528922A5/ja
Application granted granted Critical
Publication of JP7336434B2 publication Critical patent/JP7336434B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020505412A 2017-08-01 2018-07-02 アデノシン受容体アンタゴニストとしてのチアゾロピリジン誘導体 Active JP7336434B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17184272.7 2017-08-01
EP17184272 2017-08-01
PCT/EP2018/067797 WO2019025099A1 (en) 2017-08-01 2018-07-02 THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS

Publications (3)

Publication Number Publication Date
JP2020528922A JP2020528922A (ja) 2020-10-01
JP2020528922A5 true JP2020528922A5 (enExample) 2022-10-04
JP7336434B2 JP7336434B2 (ja) 2023-08-31

Family

ID=59506176

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020505412A Active JP7336434B2 (ja) 2017-08-01 2018-07-02 アデノシン受容体アンタゴニストとしてのチアゾロピリジン誘導体

Country Status (22)

Country Link
US (1) US11186592B2 (enExample)
EP (1) EP3661941B1 (enExample)
JP (1) JP7336434B2 (enExample)
KR (1) KR102717280B1 (enExample)
CN (1) CN110997681B (enExample)
AU (1) AU2018309265B2 (enExample)
CA (1) CA3071575A1 (enExample)
DK (1) DK3661941T3 (enExample)
ES (1) ES2940407T3 (enExample)
FI (1) FI3661941T3 (enExample)
HR (1) HRP20230251T1 (enExample)
HU (1) HUE061308T2 (enExample)
IL (1) IL272284B2 (enExample)
LT (1) LT3661941T (enExample)
PL (1) PL3661941T3 (enExample)
PT (1) PT3661941T (enExample)
RS (1) RS64035B1 (enExample)
SG (1) SG11202000823WA (enExample)
SI (1) SI3661941T1 (enExample)
TW (1) TWI850199B (enExample)
WO (1) WO2019025099A1 (enExample)
ZA (1) ZA202001295B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR117844A1 (es) * 2019-01-22 2021-09-01 Merck Patent Gmbh Derivados de tiazolopiridina como antagonistas del receptor de adenosina
CN112174943A (zh) * 2019-07-03 2021-01-05 四川大学 一种吲哚-2-酮类化合物在制备防治口腔细菌产品中的用途
EP4351640A1 (en) 2021-06-07 2024-04-17 Ares Trading S.A. Combination treatment of cancer
MX2025000931A (es) 2022-08-02 2025-03-07 Merck Patent Gmbh Nuevas formas cristalinas de [7-(3,6-dihidro-2h-piran-4-il)-4-metoxi-tiazolo[4,5-c]piridin-2-il]-amida de acido (s)-7-oxa-2-aza-espiro[4.5]decano-2-carboxilico y formas cocristalinas de las mismas

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4207554A (en) 1972-08-04 1980-06-10 Med-El Inc. Method and apparatus for automated classification and analysis of cells
US4125828A (en) 1972-08-04 1978-11-14 Med-El Inc. Method and apparatus for automated classification and analysis of cells
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CA2242425C (en) 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
US6579868B1 (en) 1998-01-05 2003-06-17 Eisai Co., Ltd. Purine derivatives and adenosine A2 receptor antagonists serving as preventives/remedies for diabetes
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
WO2001002400A1 (en) 1999-07-02 2001-01-11 Eisai Co., Ltd. Fused imidazole compounds and remedies for diabetes mellitus
BR0111230A (pt) 2000-05-31 2003-06-10 Astrazeneca Ab Composto, e, uso e processo para a preparação do mesmo
RU2251419C2 (ru) * 2000-06-21 2005-05-10 Ф. Хоффманн-Ля Рош Аг Производные бензотиазола
KR20030014425A (ko) 2000-07-07 2003-02-17 앤지오젠 파마슈티칼스 리미티드 혈관 손상제인 콜치놀 유도체
EE200300015A (et) 2000-07-07 2004-10-15 Angiogene Pharmaceuticals Limited Kolhinooli derivaadid kui angiogeneesi inhibiitorid
WO2004089942A2 (en) 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
US6713499B2 (en) * 2001-12-12 2004-03-30 Hoffman-La Roche Inc. 7-Amino-benzothiazole derivatives
JP2005516917A (ja) 2001-12-12 2005-06-09 アメリカ合衆国 細胞外アデノシン阻害剤およびアデノシン受容体阻害剤を用いて免疫応答および炎症を増強するための方法
WO2004092171A2 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolo[1,5-a]pyrimidines and pyrazolo[1,5-a]pyrimidines useful as a2a adenosin e receptor antagonists
US6872833B2 (en) * 2003-04-14 2005-03-29 Hoffmann-La Roche Inc. Adenosine receptor ligands
ATE389652T1 (de) * 2003-05-19 2008-04-15 Hoffmann La Roche Benzothiazol-derivate als liganden des adenosinrezeptors
WO2005028484A1 (en) * 2003-09-19 2005-03-31 F. Hoffmann-La Roche Ag Thiazolopyridine derivatives as adenosine receptor ligands
AU2005263500B2 (en) 2004-07-22 2011-02-24 F. Hoffmann-La Roche Ag Benzothiazole derivatives
KR101077295B1 (ko) * 2006-05-18 2011-10-26 에프. 호프만-라 로슈 아게 아데노신 ａ2ｂ 수용체 길항물질로서의 티아졸로-피라미딘/피리딘 우레아 유도체
US8168785B2 (en) * 2009-06-17 2012-05-01 Biotie Therapies, Inc. Benzothiazole derivatives
GB201416754D0 (en) * 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds

Similar Documents

Publication Publication Date Title
JP2020531531A5 (enExample)
JP2020531526A5 (enExample)
RU2506256C2 (ru) Лиганды для визуализации иннервации сердца
JP2019104748A5 (enExample)
JP2022524914A5 (enExample)
CA2324418A1 (en) Novel opiate compounds, methods of making and methods of use
EA200970171A1 (ru) Производные n-(аминогетероарил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии
JP2023504542A5 (enExample)
JP2019077713A5 (enExample)
EA201070874A1 (ru) Производные индол-2-карбоксамидов и азаиндол-2-карбоксамидов, замещённых силанильной группой, их получение и применение в терапии
RU2009115653A (ru) Производные 5-замещенного хиназолинона, содержащие их композиции и способы их применения
DK191186A (da) Indolderivater
CA2457054A1 (en) Activator of peroxisome proliferator-activated receptor .delta.
RU2010148559A (ru) Усиливающие заряд добавки для электретов
EA201070871A1 (ru) Бициклические производные азабициклических карбоксамидов, их получение и их применение в терапии
JP2018516904A5 (enExample)
AR063804A1 (es) Compuestos de azoniabiciclo[2.2.2]octano
RU2009125439A (ru) Комбинация ингибитора гда и антиметаболита
MX2024008480A (es) Compuesto heterociclico que contiene nitrogeno que tiene un efecto de activacion del factor 2 relacionado con el factor nuclear eritroide 2 (nrf2).
GB1046506A (en) Guanidine compounds and process for their manufacture
JP2018510202A5 (enExample)
RU2008146751A (ru) Новые производные имидазола, их получение и использование в качестве лекартвенных средств
KR920701178A (ko) 3-아릴옥사졸리디논 유도체, 그의 제조방법 및 그의 치료 용도
RU2017133660A (ru) Новые гетероциклические соединения и их применение в профилактике или лечении бактериальных инфекций
JP2025510945A5 (enExample)